A Phase 1 interventional study of Atorvastatin and LY2189265 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess if giving LY2189265 at the same time as atorvastatin affects how the body absorbs atorvastatin.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2. Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3.
Drug: Atorvastatin · Biological: LY2189265
Administered orally.
Administered subcutaneously.
Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax)
Time frame: Pre-dose to 56 hours post-dose
Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC)
This measure is based on the pharmacokinetic area under the atorvastatin plasma concentration-time curve from time 0 to infinity.
Time frame: Pre-dose to 56 hours post-dose
Pharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax)
Time frame: Pre-dose to 56 hours post-dose
Pharmacokinetics of Para-Hydroxyatorvastatin: Area Under the Curve (AUC)
This measure is based on the pharmacokinetic area under the para-hydroxyatorvastatin concentration-time curve from time 0 to infinity. The outcome is not available for this metabolite since the terminal elimination phase was not determinable.
Time frame: Pre-dose to 56 hours post-dose
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax)
Time frame: Pre-dose to 56 hours post-dose
Pharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC)
This measure is based on the pharmacokinetic area under the ortho-hydroxyatorvastatin concentration-time curve from time 0 to infinity.
Time frame: Pre-dose to 56 hours post-dose
| Milestone | LY2189265 + Atorvastatin |
|---|---|
| Started | 27 |
| Completed | 27 |
| Not completed | 0 |
| nanogram per milliliter (ng/mL) | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|
| Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) | 19.5 ± 60 | 5.78 ± 86 |
This measure is based on the pharmacokinetic area under the atorvastatin plasma concentration-time curve from time 0 to infinity.
| nanogram*hour per milliliter (ng*h/mL) | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|
| Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC) | 82.8 ± 33 | 65.9 ± 35 |
| nanogram per milliliter (ng/mL) | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|
| Pharmacokinetics of Para-Hydroxyatorvastatin: Maximum Concentration (Cmax) | 0.473 ± 81 | 0.360 ± 69 |
This measure is based on the pharmacokinetic area under the para-hydroxyatorvastatin concentration-time curve from time 0 to infinity. The outcome is not available for this metabolite since the terminal elimination phase was not determinable.
No measurements were reported for this outcome.
| nanogram per milliliter (ng/mL) | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|
| Pharmacokinetics of Ortho-Hydroxyatorvastatin: Maximum Concentration (Cmax) | 14.4 ± 46 | 5.66 ± 60 |
This measure is based on the pharmacokinetic area under the ortho-hydroxyatorvastatin concentration-time curve from time 0 to infinity.
| nanogram*hour per milliliter (ng*h/mL) | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|
| Pharmacokinetics of Ortho-Hydroxyatorvastatin: Area Under the Curve (AUC) | 102 ± 30 | 95.9 ± 28 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 40 mg Atorvastatin Alone | — | 0/27 (0%) | 8/27 (29.6%) |
| 1.5 mg LY2189265 | — | 0/27 (0%) | 23/27 (85.2%) |
| 1.5 mg LY2189265 + 40 mg Atorvastatin | — | 0/27 (0%) | 16/27 (59.3%) |
| Event | 40 mg Atorvastatin Alone | 1.5 mg LY2189265 | 1.5 mg LY2189265 + 40 mg Atorvastatin |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 0/27 | 12/27 | 3/27 |
| Abdominal distensionGastrointestinal disorders | 0/27 | 9/27 | 1/27 |
| NauseaGastrointestinal disorders | 0/27 | 9/27 | 3/27 |
| VomitingGastrointestinal disorders | 0/27 | 4/27 | 4/27 |
| Abdominal painGastrointestinal disorders | 0/27 | 0/27 | 3/27 |
| DyspepsiaGastrointestinal disorders | 0/27 | 1/27 | 3/27 |
| HeadacheNervous system disorders | 0/27 | 3/27 | 1/27 |
| LethargyNervous system disorders | 0/27 | 3/27 | 0/27 |
| Abdominal discomfortGastrointestinal disorders | 0/27 | 2/27 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 1/27 | 0/27 | 2/27 |
| Age, Continuous(years) | LY2189265 + Atorvastatin |
|---|---|
| Mean | 42.7 ± 15.1 |
| Sex: Female, Male(Participants) | LY2189265 + Atorvastatin |
|---|---|
| Female | 12 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | LY2189265 + Atorvastatin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | LY2189265 + Atorvastatin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | LY2189265 + Atorvastatin |
|---|---|
| United Kingdom | 27 |
The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Dulaglutide